Fatty liver disease is widely assumed to be a problem of excess weight, which means people with a normal BMI may never be screened, and may be falsely reassured by a healthy-looking scale reading. A cohort study in JAMA tests that assumption by comparing lean individuals with metabolic dysfunction–associated steatotic liver disease (MASLD) against those with overweight or obesity, using biopsy-based histology, long-term outcomes, and the performance of noninvasive fibrosis tests. The central question is whether lean MASLD is a milder condition or simply a less visible one.

The study characterizes clinical profiles, liver histology (steatosis, inflammation, ballooning, and fibrosis stage), and prognosis across body-size groups, while also evaluating how well commonly used noninvasive scores identify advanced fibrosis in lean patients. Full effect sizes and cohort numbers are best taken from the paper itself, but the design addresses two practical gaps: whether lean patients show comparable tissue injury, and whether the screening tools built largely on heavier populations remain accurate in them.

Prior work has been inconsistent. Some analyses suggest lean MASLD often reflects visceral fat, insulin resistance, or genetic susceptibility despite low BMI, and that fibrosis, once present, drives outcomes similarly regardless of weight. Others report better liver outcomes in lean patients but higher-than-expected mortality in specific subgroups. Histology-anchored data are valuable because they avoid relying on imaging or blood-test proxies, which may misclassify risk at the lower end of the BMI range.

Two limitations deserve attention. Biopsy cohorts are drawn from patients referred for clinical suspicion, so they likely overrepresent higher-risk individuals and may not reflect lean people in the general population. Observational designs also cannot separate the effect of body composition from unmeasured factors such as waist circumference, diet, or genetics. Editorially, this looks confirmatory rather than paradigm-shifting, but it reinforces a useful point: normal weight does not exclude liver disease. Lean adults with diabetes, elevated triglycerides, high blood pressure, or abnormal liver enzymes may reasonably raise liver health with their clinician rather than assume they are protected.